Thought Leader Liaison - Pulmonology
About the job
- 8+ years of experience in the pharmaceutical, biotech, or related industry in customer-facing roles.
- 5+ years of experience in thought leader engagement, medical affairs, marketing, sales or sales leadership, or clinical experience.
- 3+ years of experience working within Ophthalmology.
- Experience developing and executing healthcare professional key strategies.
- Proven ability to develop and execute key opinion leader mapping and plans and build key opinion leader advocacy in targeted therapeutic areas.
- Clinical, technical, and scientific knowledge and proficiency in complex disease states.
- Existing relationships with key opinion leaders, opinion leaders, and centers of excellence.
- Strong relationship-building skills, including the ability to build and maintain lasting relationships with key opinion leaders and navigate strategic accounts such as Integrated Delivery Networks, Academic Medical Centers, and Centers of Excellence.
- Ability to exercise strong decision-making skills and uphold high ethical standards.
- Excellent written and verbal communication skills, including confident executive presence.
- Ability to build productive partnerships and collaborate effectively in a matrix organization.
- Ability to creatively address problems in an organized, systematic way.
- High organizational awareness and the ability to understand interdependencies and the broader business context.
- Exceptional critical thinking to identify educational gaps, analyze findings, make recommendations, and articulate next steps.
- Strong understanding of the legal and regulatory environment for pharmaceutical promotional activities, pharmaceutical industry guidelines, and compliance-related issues.
- Bachelor's degree.
- Willingness to travel extensively, including regular business travel of 50%–65%.
- Willingness to work evenings and selected weekends.
- Location near a hub airport is recommended.
- Identify, cultivate, and maintain professional relationships with established and emerging regional key opinion leaders in targeted specialties.
- Support deep engagement with key opinion leaders, including navigating Integrated Delivery Networks, Centers of Excellence, and professional organizations.
- Identify, map, and manage relationships with key national associations and large treatment facilities, including detailed mapping of referral patterns, key relationships, and influencers.
- Coordinate and lead one-to-one exchanges between the company team and key opinion leaders across key initiatives and events.
- Attend and manage brand activity at key regional and targeted national conferences, potentially including Rheumatology, Nephrology, Pulmonology, and Ophthalmology.
- Manage overall regional sponsorships, work with organizations to secure sponsorships, and own the regional congress plan.
- Coordinate executive meetings with key opinion leaders at national conferences.
- Support conference and speaker contract requirements in a timely manner.
- Coordinate with marketing to ensure all congress materials are delivered on time.
- Work cross-functionally to drive and develop aligned external engagement strategies across medical, training, marketing, and sales teams.
- Coordinate with the sales team to align on conference key opinion leader engagement plans and other key opinion leader and account engagement.
- Provide market insights to the marketing team and contribute to peer-to-peer development, advisory boards, and strategy.
- Support the Marketing team in developing board strategy, content, and advisory recommendations, and attend advisory boards as appropriate.
- Coordinate with the Market Development Manager and Speaker Programs Management on key opinion leader speaker bureau relationships, including supporting speaker training.
- Provide insights summaries from key congresses to the marketing team.
- Develop, manage, and engage key opinion leaders throughout the assigned geography.
- Manage speakers and capture key opinion leader beliefs and insights.
- Work independently and effectively with limited direction.
- Support the Immunology Business Unit and travel frequently within the United States, with periodic travel to the corporate office.
- MBA or another advanced degree.
- Experience developing and executing healthcare professional key strategies.
- Existing relationships with key opinion leaders, opinion leaders, and centers of excellence.
- Location near a hub airport.
About the company
Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Hazelwood, Missouri
Founded
1867
Get referred to Mallinckrodt
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 net sales from continuing operations reached $517 million, up $253 million year-over-year.
- Keenova reported $25 million synergy capture in Q2 2026, targeting $100 million this year.
- XIAFLEX plantar fibromatosis Phase 3 was positive July 8, 2026, supporting a Q4 submission.
What critics are saying
- Maine DEP sued Mallinckrodt on August 25, 2026 over Orrington cleanup failures.
- The court complaint demands soil removal, sewer-line excavation, penalties, and compliance within 30 days.
- Environmental liabilities plus recurring litigation threaten cash, management attention, and creditor confidence through 2026.
What makes Mallinckrodt unique
- Keenova's Acthar Gel and XIAFLEX delivered $355 million quarterly sales in Q2 2026.
- July 2025 Endo merger created branded specialty depth plus generics and injectables separation.
- Christiana Stamoulis joined September 22, 2025, adding M&A and integration discipline.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Relocation Assistance
Growth & Insights and Company News
6 month growth
↓ -5%1 year growth
↓ -5%2 year growth
↓ -5%Maine DEP sues Mallinckrodt over failures to clean up contaminated Orrington site. The Department of Environmental Protection has filed a lawsuit against Mallinckrodt US LLC, accusing the company of failing to clean up mercury contamination at its site in Orrington. The department filed the complaint in Penobscot Superior Court Tuesday, and in court records the department said the company has stopped "meaningful work" at the site despite department orders and notices of violations. Jesse Graham is the co-director of the Maine People's Alliance - which, independent from the state enforcement actions, sued Mallinckrodt over the contamination in federal court in 2000. "We have for a long time been calling for the thorough cleanup of that site, and we have definitely been disappointed that Mallinckrodt has not cleaned it up to the standards that the Maine DEP has set," Graham said. "We fully support the Maine DEP continuing to pressure them and whatever legal tactics they need to do to compel them to finish and do a thorough cleanup of all the pollution that Mallinckrodt has left on the site." Considered the most contaminated site in Maine, the property is the former HoltraChem chloralkali manufacturing facility. Located adjacent to the Penobscot River, the facility operated from 1967 through 2000, and manufactured caustic soda, chlorine bleach and pesticides. In court documents, the department said Mallinckrodt has complained about the difficulties and high costs of cleaning up the site. But, the department said, "this is no excuse for Mallinckrodt's ongoing failure to adhere to the cleanup standards and other requirements of the orders." The department is asking the court for civil penalties, and to order Mallinckrodt to comply with all department orders and submit a plan to remove all soil and solid materials from the site. Attempts to reach someone who could speak on behalf of Mallinckrodt were unsuccessful. The DEP and the U.S. Environmental Protection Agency first began pursuing clean up at the site in the mid-1980s, including negotiations with the company in 2002. But after failing to reach an agreement, in 2008 the department issued a unilateral cleanup order for the site. But Mallinckrodt appealed that order, first to the Board of Environmental Protection, and then in state courts. Ultimately, the state supreme court upheld the department's order in 2014. The department issued notices of violations to Mallinckrodt in May and October of 2025, over the ongoing issues, but said the company still failed to address the shortcomings of their proposed cleanup plans. There is also the federal court case filed by the Maine People's Alliance, which is separate from the state proceedings involving the department. In 2022, Mallinckrodt settled the federal case, and agreed to pay at least $187 million to address mercury pollution in the Penobscot River. Graham said some of that agreed-up work is underway now, as Mallinckrodt adds sand to several coves along the river with high levels of mercury, a process known as "capping."
DEP sues to compel cleanup of 'most contaminated site in Maine' BY Susan Cover Maine PUBLISHED 10:13 AM ET Aug. 27, 2026 AUGUSTA - State officials are escalating action against a company they say has failed to clean up "the most contaminated site in Maine" after more than 20 years of lawsuits. The Maine Department of Environmental Protection filed a formal complaint Tuesday in Penobscot County Superior Court against Mallinckrodt US LLC. The state alleges that the company has failed to clean up the former HoltraChem site on the Penobscot River in Orrington. The site "discharged to the environment tons of mercury and thousands of tons of mercury-contaminated brine-sludge, substances that are defined as hazardous wastes," according to the lawsuit. The facility made chemicals commonly used in the pulp and paper industry, according to DEP. It operated under various owners from 1967 to 2000. The company did not respond to a request for comment. The suit says the facility covered about 235 acres near the river, 77 of which were affected by the production. The site included five landfills, a manufacturing facility and waste piles. In the mid-1980s, the U.S. Environmental Protection Agency and the state began investigating the site and calling for remediation. According to the suit, in 2000, the Maine People's Alliance and the Natural Resources Defense Council filed a lawsuit against the company alleging that the company "discharged mercury from the site into the Penobscot River and that these discharges resulted in an imminent and substantial danger to public health and the environment." A court ordered the company to come up with a remediation plan. The latest lawsuit asks the court to remove contaminated soil and industrial sewer lines, assess civil penalties and require the company to comply with all DEP orders.
Maine DEP sues company over cleanup of contaminated Orrington site. Mallinckrodt US LLC operated a chemical manufacturing plant along the Penobscot River in Orrington that discharged up to a dozen metric tons of mercury in the late 1960s and early 1970s. Community: Posted 7:54 PM Updated at 7:54 PM The Maine Department of Environmental Protection is suing the owners of a site in Orrington, alleging they've failed to properly clean up contamination. The Maine DEP announced the legal action in Penobscot Superior Court against Mallinckrodt US LLC on Tuesday. The department is seeking injunctive relief and civil penalties. The company operated a chemical manufacturing plant along the Penobscot River in Orrington between 1967 and 1982. While under Mallinckrodt's control, the site discharged between six and 12 metric tons of mercury in the late 1960s and early 1970s, according to one court-ordered study. Please add a subscription to your account to access this story. Choose a plan to keep reading. Starter Digital $1 for 4 weeks * | 4 weeks of access for $1 * | Full access to our websites, ePapers and app * | Newsletters, archives, puzzles and games * | In-depth reporting, investigations and must-read stories * | Share access with up to four other people in your household Annual Digital $99 per year Billed annually - Save 56% * | One year of access for $99 * | Full access to our websites, ePapers and app * | In-depth reporting, investigations and must-read stories * | Share access with up to four other people in your household
Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...
Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.